A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

• Status: Terminated
• Trial end date: 2010-01-19
• Target enrollment: 0
• Participant gender: All

Summary

The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma?

The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: Schering-Plough
• Treatments: Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Mometasone Furoate

Criteria

Inclusion Criteria:

• subjects 18 to 65 years of age

• a >2 year history of asthma

• FEV1 > 80% for subjects currently using Advair®.

Exclusion Criteria:

• severe asthma

• current smokers

• pregnant or breast-feeding women

• other chronic significant illnesses